Table 2. Clinical features of patients... | American Society of Hematology

Table 2.

Clinical features of patients with AML

	Data
No. of patients	10
Median age, y (range)	63 (46-81)
No. of men (%)	6 (60)
AML features, no.
De novo	8
Arising from myelodysplasia	2
Arising following treatment	0
Status at time of treatment, no.
Initial therapy	2
Primary refractory disease	2
Relapsed disease, less than 12 mo	4
Relapsed disease, more than 12 mo	2
Relapse after autologous transplantation	2
Relapse after allogeneic transplantation	1
Median WBC, × 10⁹/L (range)	2.2 (0.8-16.6)
Median Hgb, g/dL, (range)	9.9 (8.3-12.7)
Median platelets, × 10⁹/L (range)	61 (10-187)
Median ECOG performance status (range)	1 (0-2)
On hydroxyurea prior to treatment, no.	2
Active problem requiring hospitalization, no.	1
CALGB cytogenetic classification, no.
Low risk	0
Intermediate risk	8
High risk	2

	Data
No. of patients	10
Median age, y (range)	63 (46-81)
No. of men (%)	6 (60)
AML features, no.
De novo	8
Arising from myelodysplasia	2
Arising following treatment	0
Status at time of treatment, no.
Initial therapy	2
Primary refractory disease	2
Relapsed disease, less than 12 mo	4
Relapsed disease, more than 12 mo	2
Relapse after autologous transplantation	2
Relapse after allogeneic transplantation	1
Median WBC, × 10⁹/L (range)	2.2 (0.8-16.6)
Median Hgb, g/dL, (range)	9.9 (8.3-12.7)
Median platelets, × 10⁹/L (range)	61 (10-187)
Median ECOG performance status (range)	1 (0-2)
On hydroxyurea prior to treatment, no.	2
Active problem requiring hospitalization, no.	1
CALGB cytogenetic classification, no.
Low risk	0
Intermediate risk	8
High risk	2